Summit Therapeutics Q3 2026 Earnings Date & Estimates

Summit Therapeutics (NASDAQ:SMMT) Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company’s primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Summit’s lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings.

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company. Akeso retains rights in China, while Summit is responsible for development and commercialization activities across its licensed international territories.

The company has roots in the United Kingdom and was historically involved in developing treatments for infectious diseases before shifting its strategic focus to oncology. Summit is led by Robert W. Duggan, who serves as chairman and chief executive officer, and conducts its clinical development and business activities through operations serving global markets.